Profile data is unavailable for this security.
About the company
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
- Revenue in EUR (TTM)186.00k
- Net income in EUR-6.46m
- Incorporated2007
- Employees12.00
- LocationCelyad Oncology SARue Andre Dumont 9MONT-SAINT-GUIBERT 1435BelgiumBEL
- Phone+32 10394100
- Fax+32 10394141
- Websitehttps://www.celyad.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvonis Therapeutics PLC | 0.00 | -2.99m | 19.58m | -- | -- | 2.13 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -44.49 | -- | -54.32 | -- | -- | -- | -- | -- | -- | -645.25 | 0.011 | -- | -100.00 | -- | 53.62 | -- | -- | -- |
| Klaria Pharma Holding AB (publ) | 1.06m | -5.54m | 19.90m | 4.00 | -- | 46.44 | -- | 18.79 | -0.4069 | -0.3093 | 0.0699 | 0.0185 | 0.201 | -- | 5.34 | 2,808,250.00 | -105.02 | -48.20 | -649.38 | -74.06 | -- | -- | -522.58 | -1,522.52 | -- | -2.47 | 0.1195 | -- | -73.41 | -11.85 | -33.44 | -- | -- | -- |
| Dextech Medical AB | 0.00 | -467.79k | 20.05m | 1.00 | -- | 8.89 | -- | -- | -0.2684 | -0.2684 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -18.58 | -19.36 | -18.94 | -19.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.96 | -- | 40.14 | -- |
| Fusion Antibodies PLC | 1.84m | -1.69m | 20.13m | 24.00 | -- | 21.92 | -- | 10.97 | -0.0144 | -0.0144 | 0.0152 | 0.0064 | 0.9557 | 4.96 | 1.96 | 66,500.00 | -87.84 | -56.24 | -137.88 | -73.67 | 22.06 | 36.41 | -91.92 | -71.05 | 1.45 | -190.63 | 0.3483 | -- | 72.98 | -12.79 | 23.05 | -- | -37.98 | -- |
| Helyx Industries SpA | 925.86k | -5.30m | 20.16m | 23.00 | -- | 0.8922 | 302.74 | 21.78 | -0.205 | -0.205 | 0.0359 | 0.8675 | 0.0345 | 0.9108 | 2.74 | 40,254.78 | -19.77 | -19.75 | -21.32 | -21.62 | -86.89 | -213.90 | -572.63 | -740.61 | 1.48 | -311.98 | 0.0451 | -- | 1,059.84 | 134.89 | -23.83 | -- | -10.84 | -- |
| Xbrane Biopharma AB | 19.72m | -6.87m | 20.38m | 26.00 | -- | 0.3681 | -- | 1.03 | -5.16 | 8.99 | 14.57 | 28.49 | 0.2713 | 0.2899 | 5.00 | 3,216,539.00 | -9.46 | -37.48 | -15.30 | -65.13 | 71.25 | -- | -34.85 | -233.69 | 1.71 | -1.49 | 0.00 | -- | -16.76 | -- | 17.70 | -- | 113.17 | -- |
| AlzeCure Pharma AB | 0.00 | -3.70m | 20.53m | 11.00 | -- | 4.30 | -- | -- | -0.4047 | -0.4047 | 0.00 | 0.4409 | 0.00 | -- | -- | 0.00 | -71.83 | -73.70 | -88.08 | -83.65 | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | 5.20 | -- | -38.94 | -- |
| Arterra Bioscience SpA | 4.49m | 1.90m | 20.77m | 37.00 | 10.37 | 1.69 | 9.33 | 4.62 | 0.3008 | 0.3008 | 0.7097 | 1.84 | 0.3385 | 1.37 | 4.10 | 132,186.50 | 14.35 | 10.33 | 15.55 | 11.35 | 63.60 | 59.90 | 42.38 | 34.18 | 6.31 | -- | 0.0258 | -- | 26.30 | 9.02 | 24.21 | 9.29 | -16.17 | -- |
| Urteste SA | 0.00 | -1.30m | 20.93m | 34.00 | -- | 3.76 | -- | -- | -3.88 | -3.88 | 0.00 | 15.35 | 0.00 | -- | -- | -- | -15.56 | -29.65 | -18.99 | -31.35 | -- | -45,933.33 | -- | -623,333.30 | -- | -- | 0.0128 | -- | -- | -- | 35.00 | -- | 197.79 | -- |
| Xintela AB | 278.84k | -3.99m | 21.44m | 13.00 | -- | -- | -- | 76.89 | -0.0665 | -0.0665 | 0.0046 | -0.0396 | 0.3486 | -- | 6.47 | 227,461.50 | -498.42 | -194.17 | -- | -651.77 | 100.00 | -- | -1,429.86 | -6,272.93 | -- | -16.40 | -- | -- | 5,303.85 | 156.45 | 27.54 | -- | -- | -- |
| Sprint Bioscience AB | 15.76m | 8.65m | 21.59m | 30.00 | 2.60 | 1.92 | 2.47 | 1.37 | 0.8333 | 0.8333 | 1.79 | 1.13 | 1.87 | -- | 18.22 | 5,572,267.00 | 102.66 | -4.00 | 142.84 | -6.12 | 92.19 | 76.93 | 54.88 | -3.84 | -- | 17.51 | -- | -- | 154.67 | 58.17 | 601.92 | -- | -- | -- |
| Nanogroup SA | -1.64k | -1.64m | 21.70m | -- | -- | 7.84 | -- | -- | -0.1844 | -0.1844 | -0.0002 | 0.3553 | -0.0003 | 2.64 | -- | -- | -30.59 | -29.50 | -51.55 | -33.80 | -- | 66.72 | -- | -2,258.26 | 0.9785 | -464.18 | 0.00 | -- | 3.96 | -64.09 | 34.50 | -- | 3.07 | -- |
| Celyad Oncology SA | 186.00k | -6.46m | 22.16m | 12.00 | -- | -- | -- | 119.12 | -0.1558 | -0.1558 | 0.0045 | -0.0749 | 0.0201 | -- | 3.80 | 15,500.00 | -69.62 | -42.66 | -104.04 | -53.33 | 94.09 | 72.35 | -3,470.43 | -33,762.12 | 0.5921 | -257.64 | -- | -- | 82.35 | 98.73 | 31.06 | -- | -28.28 | -- |
| Promimic AB | 4.30m | -1.14m | 22.54m | 18.00 | -- | 3.92 | -- | 5.24 | -0.6388 | -0.6388 | 2.40 | 3.23 | 0.603 | -3.56 | 3.62 | 2,398,421.00 | -16.05 | -20.50 | -18.57 | -24.44 | 105.07 | 104.49 | -26.62 | -59.75 | 3.52 | -- | 0.00 | -- | 18.63 | 50.25 | -36.09 | -- | -- | -- |
| Circio Holding ASA | 0.00 | -816.12k | 23.16m | 9.00 | 10.00 | -- | -- | -- | 0.1348 | 0.1348 | 0.00 | -0.0836 | 0.00 | -- | -- | 0.00 | -93.87 | -47.84 | -- | -58.78 | -- | -- | -- | -6,460.26 | -- | -- | -- | -- | -100.00 | -- | 150.93 | -- | 7.12 | -- |
| Valbiotis SA | 472.00k | -11.12m | 24.55m | 44.00 | -- | 2.09 | -- | 52.02 | -0.6994 | -0.6994 | 0.0297 | 0.4967 | 0.0206 | 1.57 | 4.89 | 10,727.27 | -48.58 | -33.12 | -61.97 | -47.09 | -603.81 | 19.74 | -2,354.87 | -464.77 | 2.93 | -74.38 | 0.3129 | -- | -96.30 | 13.97 | -36.06 | -- | -2.02 | -- |
Data as of Feb 17 2026. Currency figures normalised to Celyad Oncology SA's reporting currency: Euro EUR
0.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BNP Paribas Asset Management Belgium SAas of 30 Jan 2026 | 33.74k | 0.08% |
Data from 12 Feb 2026 - 12 Feb 2026Source: FactSet Research Systems Inc.
